Montreal, Quebec Province, Canada
McGill University Health Centre (MUHC) and Research Institute of the MUHC (RI-MUHC) inaugurated a new research institute that was jointly built at MUHC’s Glen, Montreal site in February 2015.
The Glen site, which is one of the most innovative academic health centres in North America, is located at the centre of three vibrant neighbourhoods of Montreal city, Notre-Dame-de-Grace, Sud-Ouest and Westmount in Quebec Province.
The new research institute is a part of MUHC’s Redevelopment Project at the Glen site. It offers biomedical and research facilities, and features renovated labs and redesigned care units to facilitate fundamental research for establishing the MUHC as a world-class centre of excellence in patient-centric medicine.
The current research institute at the MUHC will be moved to the new facility at the Glen site by the end of February 2015.
RI-MUHC, with an objective to establish MUHC as a cutting-edge centre of excellence, adopted a strategic plan which includes a new programme-based framework that will guide its future research activities.
Construction of a new state-of-the-art research institute at the Glen site is the first step towards achieving this objective.
As part of the plan, the laboratories and clinical research facilities at Montreal General Hospital (MGH), which houses one-third of the research institute’s community, will also be modernised to provide better research facilities for the investigators at the MGH.
Construction works at the site began in June 2010, and the research building was completed in the third calendar quarter of 2014.
The new research centre, located in Block E on the south-east side of the Glen site, is a five-storey building comprising two towers with a central atrium.
The facility is built-up with a total area of 450,000ft², and is connected to the hospital building by a suspended walkway.
The research facility is being built by replacing Hayden Harris Hall located at the university campus in Baltimore, US, and will house a state-of-the-art collaborative research space.
Research activities at the new RI-MUHC are housed in two main centres, which include the Centre for Translational Biology (CTB) and the McConnell Centre for Innovative Medicine (CIM).
These two centres, along with other clinical research units at the site such as the Centre for Outcome Research and Evaluation (CORE), are expected to take research at the MUHC to the next level.
CTB, located in Block E on levels S1-3 of the research building, houses 110 biomedical scientists.
It conducts fundamental research and features 105 lab modules, 210 equipment alcoves, 29 equipment rooms, 18 freezer rooms, seven tissue culture units, seven radioisotope labs, 14 cold rooms, seven glass washing rooms, and a state-of-the-art technical platform.
The CIM, integrated with the hospital, is located on level four of blocks B and C of the Glen site. It will be used by more than 250 clinical and evaluative researchers to conduct research and clinical trials to discover new treatments.
In addition, it houses three clinical research pods with a total of nine beds (eight for adults and one for children), an imaging and functional platform, offices and support spaces.
The state-of-the-art equipment at the RI-MUHC includes a CT scan, a fluoroscopy machine, two nuclear magnetic resonance (NMR) spectrometers, mass spectrophotometers, and microscopes including confocal microscopes.
Technological platforms are equipped with clinical proteomics, immune phenotyping, cellular imaging and histopathology core facilities.
Other facilities for research staff include conference and team rooms, a large amphitheatre with a capacity of 200 seats, staff locker rooms, lounges, kitchen, offices and student work rooms.
Spread across an area of 43 acres, the Glen site will bring ambulatory services and world-class teaching, research and patient care under one roof.
The site features new facilities for the Royal Victoria Hospital, the Montreal Children’s Hospital, the Montreal Chest Institute, the Cancer Centre and the MUHC Research Institute. It includes 20 operating rooms, 154 paediatric and 346 adult single-patient rooms, space for visitors, and two parking garages to accommodate 2,859 vehicles.
The Glen site is scheduled for opening in April 2015.
The design-build contract for the Glen campus was awarded to McGill Health Infrastructure Group (MHIG), which is a consortium of SNC-Lavalin and Innisfree.
Under the 34-year public-private partnership (PPP), the consortium is responsible to design, build, finance and maintain the new Glen campus. The MHIG will maintain the campus for 30 years once it becomes operational.
The redevelopment project at the Glen site was jointly funded by the MUHC and MHIG. For the research institute, the MUHC invested a total of $320m, of which $220m was allocated for construction and design, and $100m for research equipment and personnel.
Funding was secured from the government of Quebec ($100m), Canada Foundation for Innovation (CFI, $100m), MUHC ($70m) and donations to the MUHC foundations through the Best Care for Life campaign ($50m).
Vibalogics announced the development of a late-phase clinical and commercial virotherapy manufacturing facility in Boston, Massachusetts, US, in November 2020.…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Arranta Bio is constructing a new multi-product, commercial-ready manufacturing facility in Watertown, Massachusetts, US. Watertown facility will be used for…
Berkshire Sterile Manufacturing (BSM) is expanding its manufacturing facility in Lee, Massachusetts (MA), US. The company began preparations for the…